Articles tagged with Pulmonary Hypertension
Scientists have made significant discoveries in the treatment of sinus node dysfunction, lupus, and cardiac failure, while also uncovering new mechanisms for bacterial defense and asthma treatment. These findings hold promise for developing more effective therapies.
German researchers found oral sildenafil improves hemodynamics and exercise capacity in patients with chronic thromboembolic pulmonary hypertension. A study also revealed African-American children have a much higher hospital readmission rate for asthma, over four times that of other races/ethnicities.
Researchers at UCSD identified a key gene pathway contributing to pulmonary hypertension, with potential molecular targets for new therapies. The study revealed that abnormal expression of angiopoietin-1 leads to muscle cell proliferation in lung vessels, causing disease progression.
A randomized controlled trial found that sildenafil reduced pulmonary blood resistance, a key indicator of pulmonary hypertension. The study suggests sildenafil could be a promising candidate for long-term treatment of secondary pulmonary hypertension in lung fibrosis. Controlled trials are needed to confirm the findings.
A recent study found that stress increases anxiety and depression scores in college students with mild allergic asthma, leading to enhanced airway inflammation. In contrast, intravenous sildenafil reversed vascular resistance in an animal model of neonatal pulmonary hypertension, offering new hope for treating this serious condition.
Researchers investigated bosentan's effectiveness in treating patients with severe pulmonary hypertension. Bosentan improved cardiopulmonary haemodynamics and reduced pulmonary artery pressure in patients compared to placebo.
A first-of-its-kind oral drug, bosentan, has been shown to reverse the deadly consequences of primary pulmonary hypertension (PPH) and improve patients' quality of life. By increasing exercise capacity and improving heart function, bosentan reduces symptoms such as shortness of breath and fatigue.
New research found that 13 of 50 people with primary pulmonary hypertension shared a genetic defect in the BMPR-II gene, similar to those with familial forms. This discovery has important implications for treatment and future therapies focused on altered cell signals.
Researchers have identified a gene associated with inherited primary pulmonary hypertension, providing new avenues of study for determining its molecular basis. The discovery opens up possibilities for designing more effective therapies for this devastating condition, which affects primarily women of childbearing age.
Researchers have identified a bone morphogenetic protein receptor II gene mutation as the cause of familial primary pulmonary hypertension, a progressive condition characterized by constriction of blood vessels. The discovery could lead to earlier diagnosis and more effective treatments for both familial and sporadic forms of PPH.
Scientists at HSC have successfully reversed fatal pulmonary hypertension in an animal model using an elastase inhibitor, which stops disease progression and restores normal blood vessel function. This breakthrough research may lead to new treatments for other cardiovascular conditions.